The enhancement of morphine antinociception by a CCK(B) receptor antagonist in the rat depends on the phase of inflammation and the intensity of carrageenin-induced hyperalgesia

Pain

Volumn 74, Issue 2-3, 1998, Pages 269-274

  Perrot, Serge ^a,b   Idänpään Heikkilä, Juhana J ^a,c   Guilbaud, Gisèle ^a   Kayser, Valérie ^a  

^a INSERM   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antinociception; Carrageenin; CCK(B) receptor antagonist; Morphine; Paw pressure; Rat

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CARRAGEENAN; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; MORPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT;

ANIMALS; BENZODIAZEPINONES; CARRAGEENAN; DRUG SYNERGISM; EXCIPIENTS; HYPERALGESIA; MALE; MORPHINE; NARCOTICS; NEURITIS; NOCICEPTORS; PHENYLUREA COMPOUNDS; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0344447092     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00178-4     Document Type: Article

References (28)

1. Baber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulein and CCK antagonists in nociception. Pain. 39:1989;307-328.
2. Beinfeld M.C., Meyuer D.K., Eskay R.L., Jensen R.T., Brownstein M.J. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res. 212:1981;51-57.
3. Chapman V., Honoré P., Buritova J., Besson J.M. Cholecystokin B receptor antagonism enhances the ability of a low dose of morphine to reduce c-Fos expression in the spinal cord of the rat. Neuroscience. 67:1995;731-739.
4. Committee for Research and Ethical Issues of the IASP, Ethical standards for investigators of experimental pain in animals. Pain. 16:1983;161-164.
5. B antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in rat. Eur. J. Pharmacol. 175:1990;35-44.
6. Fletcher D., Kayser V., Guilbaud G. The influence of the timing of bupivacaine infiltration on the time course of inflammation induced by two carrageenin injections 7 days apart. Pain. 69:1997;303-309.
7. Gall C., Lauterborn J., Burks D., Seroogy K. Co-localization of enkephalin and cholecyctokinin in discrete areas of rat brain. Brain Res. 403:1987;403-408.
8. Hill D.R., Woodruff G.N. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res. 526:1990;276-283.
9. B-receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics. Eur. J. Pharmacol. 325:1997;155-164.
10. Kayser, V., Endogenous opioid systems in the modulation of pain: behavioral studies in rat models of persistent hyperalgesia. In: G.F. Gebhart, D.L. Hammond and T.S. Jensen (Eds.), Progress in Pain Research and Management, Vol. 2, Proc. VIIth World Congress on Pain, IASP Press, Seattle, WA, 1994, pp. 553-568.
11. Kayser V., Guilbaud G. The analgesic effects of morphine, but not those of the enkephalinase inhibitor thiorphan, are enhanced in arthritic rats. Brain Res. 267:1983;131-138.
12. Kayser V., Guilbaud G. Local and remote modifications of nociceptive sensitivity during carrageenin-induced inflammation in the rat. Pain. 28:1987;99-107.
13. Kayser V., Guilbaud G. Differential effects of various doses of morphine and naloxone on two nociceptive test thresholds in arthritic and normal rats. Pain. 41:1990;353-363.
14. Kayser V., Guilbaud G. Physiological relevance and time course of a tonic endogenous opioid modulation of nociceptive messages, based on the effects of naloxone in a rat model of localized hyperalgesic inflammation. Brain Res. 567:1991;197-203.
15. Kayser V., Benoist J.M., Neil A., Gautron M., Guilbaud G. Behavioural and electrophysiological studies on the paradoxical antinociceptive effects of an extremely low dose of naloxone in an animal model of acute and localized inflammation. Exp. Brain Res. 73:1988;402-410.
16. Kayser V., Chen Y., Guilbaud G. Behavioural evidence for a peripheral component in the enhanced antinociceptive effect of a low dose of systemic morphine in carrageenin-induced hyperalgesic rats. Brain Res. 560:1991;237-244.
17. Maldonado R., Derrien M., Noble F., Roques B.P. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. NeuroReport. 4:1993;947-950.
18. O'Neill M.F. Dourish, CT. and Iversen, S.D. Morphine analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329. Neuropharmacology. 28:1989;243-248.
19. 5-enkephalin- and dynorphin A (1-8) like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J. Neurochem. 55:1990;1122-1130.
20. Singh L., Oles R.J., Field M.J., Atwal P., Woodruff G.N., Hunter J.C. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine. Br. J. Pharmacol. 118:1996;1317-1325.
21. Stanfa L.C., Dickenson A.H. Cholecystokin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br. J. Pharmacol. 108:1993;967-973.
22. Stanfa L., Dickenson A.H., Xu X.J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol. Sci. 15:1994;65-66.
23. Stengaard-Pedersen K., Larsson L.I. Localization and opiate receptor binding of enkephalin, CCK and ACTH/b-endorphin in the rat central nervous system. Peptides. 2:1981;3-7.
24. B antagonist in mice is mediated via opioid delta receptors. J. Pharmacol. Exp. Ther. 278:1996;212-219.
25. Valverde O., Maldonado R., Fournie-Zaluski M.C., Roques B.P. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Ther. 270:1994;77-88.
26. Wiesenfeld-Hallin Z., Xu X.J., Hugues J., Horwell D.C., Hökfelt T. PD 134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc. Natl. Acad. Sci. USA. 87:1990;7105-7109.
27. Wiesenfeld-Hallin Z., Xu X.J. The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Reg. Peptides. 65:1996;23-28.
28. Zhou Y., Sun Y.H., Zhang Z.W., Han J.S. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCK-B receptor antagonist L-365,260 in rat spinal cord. Eur. J. Pharmacol. 234:1993;147-154.